Introduction
Tumor microenvironment consists of tumor cells that proliferate and interact with stromal cells, neovessels and inflammatory cells (Folkman et al., 1989; Rafii et al., 2002) . A number of studies have shown that tumor growth depends on the rapid recruitment of endothelial cells (ECs), which contributes to functional neovasculature (Folkman et al., 1989; Carmeliet, 2003) . The central role of vascular endothelial growth factor (VEGF) in tumor angiogenesis makes it attractive as a target for antiangiogenic drugs (Folkman et al., 1989; Yancopoulos et al., 2000; Zachary and Gliki, 2001; Ferrara et al., 2003) . Indeed, in mouse tumor models, the introduction of factors that block different aspects of angiogenesis, including VEGF signaling, efficiently inhibits tumor growth (Lyden et al., 2001; Huang et al., 2003) . However, clinical trials with antiangiogenic factors for treatment of human malignancies have not been so effective as anticipated from animal models (Rafii et al., 2002) . These results indicate that, besides VEGF, tumor angiogenesis and growth might be orchestrated by a more complex set of growth factors. With regard to this, we have recently shown that the inflammatory cytokine interleukin-3 (IL-3) (Dentelli et al., 1999) is released into the microenvironment of breast cancer tissues (Dentelli et al., 2004) and, consistent with the original observation that activated T-lymphocytes are the main cellular source of IL-3 (Wimperis et al., 1989) , we also found that in noninvasive breast cancer tissues a subset of tumorinfiltrating CD25/CD4/CD5 þ T cells expressed IL-3 (Dentelli et al., 1999) . Moreover, we also previously showed that IL-3 is secreted by tat-expressing cells (Deregibus et al., 2002) , and that, besides tumorinfiltrating lymphocytes, tumor-derived ECs also represent an important source of IL-3 (Bussolati et al., 2003) .
Cytoskeletal rearrangement and acquisition of a motile phenotype are important steps in the development of neovasculature inside tumors (Chambers et al., 2002) . The importance of Rho family GTPases in conferring motile properties is well established (Burridge and Wennerberg, 2004) . Among the members of this family, Rac1 mainly regulates cell motility induced by growth factors (Keely et al., 1997; Bar-Sagi and Hall, 2000; Ridley, 2001; van Golen, 2003; Burridge and Wennerberg, 2004) . As VEGF, IL-3 promotes EC motility and in vivo neoangiogenesis (Dentelli et al., 1999 (Dentelli et al., , 2004 Yancopoulos et al., 2000; Ferrara et al., 2003) , however, no data are available on the signaling molecules involved in IL-3-mediated cell migration. IL-3 exerts its biological responses by interacting with an heterodimeric receptor consisting of a ligand-bindingspecific a-subunit and of a common transducing b (bc)-subunit (Hayashida et al., 1990; Kitamura et al., 1991) . Unlike VEGF receptor 2/KDR, the IL-3 receptor (IL-3R) bc is devoid of intrinsic tyrosine kinase domain; however, ligand binding induces tyrosine phosphorylation of the receptor components and activation of intracellular signaling proteins including the members of the signal transducers and activators of transcription (STAT) family (Brizzi et al., 1994; Ihle and Kerr, 1995; Mui et al., 1995 Mui et al., , 1996 Aronica et al., 1996) . The role of STAT tyrosine phosphorylation in regulating VEGF- (Korpelainen et al., 1999; Bartoli et al., 2000) and IL-3-mediated signals (Mui et al., 1995 (Mui et al., , 1996 Reddy et al., 2000) has been investigated. More recently, a secondary regulatory mechanism independent of tyrosine phosphorylation has been described for several STAT proteins that involves serine phosphorylation (Yamashita et al., 1998; Decker and Kovarik, 2000; Benitah et al., 2003) .
The expression of VEGF is nearly ubiquitous in human cancers, consistent with its role as a key regulator of tumor angiogenesis (Folkman et al., 1989; Rafii et al., 2002; Carmeliet, 2003) . However, VEGF has also been shown to act as survival factor for breast cancer cells (Bachelder et al., 2001) . Thus, despite considerable progress in understanding the intracellular mechanisms mediating the action of VEGF in the endothelium (Tanimoto et al., 2002; Thuringer et al., 2002) , important areas of VEGF receptor signal transduction remain to be elucidated. The observation that IL-3, as VEGF, is released into the tumor microenvironment (Deregibus et al., 2002; Bussolati et al., 2003; Dentelli et al., 2004) led us to investigate if and how IL-3 by itself or in cooperation with VEGF may contribute to tumor neoangiogenesis.
Results

IL-3 and VEGF enhance migration and matrix invasion
In the present study we used the murine-transformed EC line, H-END, that express IL-3 and VEGF2 receptors (Figure 1a ), as a model to study the effects exerted by IL-3 and VEGF on tumor angiogenesis. As shown in Figure 1b , as VEGF, IL-3 acts as chemoattractant for Figure 1 IL-3-and VEGF-mediated cell migration and invasion. (a) For receptor expression, cell lysates from H-END cells or EC, used as positive control, were immunoprecipitated (IP) with the anti-IL-3R bc antiserum or with the anti-KDR antiserum, subjected to 8% SDS-PAGE and the filters were immunoblotted (IB) with the anti-IL-3R bc or anti-KDR antisera, respectively. Three experiments were performed with similar results. (b) Cell migration. Wild type, or H-END cells expressing Neo-vector or IL-3R D455 mutant were treated with vehicle alone, IL-3 (20 ng/ml), VEGF (10 ng/ml) or bFGF (10 ng/ml) and assayed for in vitro migration. Numbers are the mean7s. IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al transformed ECs. To confirm the role of the IL-3R bc, H-END cells were also stably transfected with a Neo vector, or with an IL-3R bc-deleted mutant lacking the entire intracellular domain, denoted as D455. Cells obtained from five different clones were assayed for their ability to migrate in a Boyden's chamber. Both wild-type H-END and Neo-vector-expressing cells migrate in response to both IL-3 and VEGF, while the motogenic effect was completely or partially prevented by the expression of the IL-3R D455 mutant. Moreover, the results reported in Figure 1c demonstrate that the effect of VEGF on D455-expressing cells was due to a decreased expression of VEGFR2/KDR.
H-END cells were also assayed for their ability to proliferate in response to IL-3 and VEGF. Consistent with the observation that IL-3 acts as survival factor for these cells (Deregibus et al., 2002) , either IL-3 or VEGF failed to induce proliferation (data not shown), but still retain the ability to trigger Akt activation (Figure 1d ). These findings indicate that, as reported previously, IL-3 and VEGF act as survival rather then proliferating factors for these cells (Deregibus et al., 2002) .
Besides cell migration, an in vitro invasion assay was performed. Cells from wild-type and from different transfectants were seeded into transwell plates, coated with Matrigel matrix. Wild-type, Neo-vector-and D455-expressing cells were untreated or treated with IL-3 or VEGF for 24 or 48 h. Data, presented in Figure 1e , demonstrate that IL-3, as well as VEGF, induces invasiveness in wild-type and in Neo-vector H-END cells. Moreover, consistently with the results of the migration assay, in cells expressing the IL-3R D455-deleted mutant invasiveness in response to IL-3 and VEGF was abrogated and reduced, respectively. Similar results were obtained using microvascular ECs (CDC-HMEC-1 cells) (panel e).
The specific contribution of IL-3R bc to the motogenic response to VEGF is also supported by the observation that the number of migrating cells detected in the different H-END transfectants did not significantly change upon bFGF treatment (Figure 1b and e) .
Activation of IL-3R bc is a common event in IL-3-and VEGF-mediated Rac1 engagement and in vitro neoangiogenesis Small G proteins of the Rho family and in particular Rac1 have been shown to regulate the motile phenotype (Bar-Sagi and Hall, 2000; Ridley, 2001; van Golen, 2003) . As shown in Figure 2a , either IL-3 or VEGF treatment increases the amount of active GTP-bound Rac1 pull-down from Neo-vector-expressing cells, but not from cells expressing the D455 mutant. These data strongly suggest the role of Rac1 signaling pathway in regulating IL-3-and VEGF-mediated cell migration.
The acquisition of a motile phenotype is a prerequisite for ECs to initiate the sequence of events leading to neovessel formation. As shown in Figure 2b , we found that within 4 h, IL-3 and VEGF treatment cord-like structures are formed by Neo vector H-END cells, while with the IL-3R D455 mutant, only few tube-like structures could be detected both in untreated and IL-3-or VEGF-treated cells. Collectively, the observations that the expression of the D455 mutant not only abrogates the effects of IL-3 but also partially reduces the effect of VEGF on Rac1 activation and on in vitro neoangiogenesis suggest a role of the IL-3R bc in the signaling pathways activated by VEGF.
VEGF and IL-3 treatment induces the formation of an IL-3R bc/KDR molecular complex
The above findings suggest that VEGF-mediated biological response can be modulated by the activation of the IL-3R bc. Thus, we first analysed the ability of VEGF to trigger the activation of the IL-3R on human primary ECs. As shown in Figure 3a , the anti-IL-3R bc antibody was able to precipitate two phosphoproteins (left panel) of about 130 and 210 kDa, respectively, only upon VEGF treatment. Moreover, the anti-KDR and anti-IL-3R bc immunoblots of the anti-IL-3R bc and anti-KDR immunoprecipitates, respectively, clearly demonstrated that KDR and the IL-3R bc are indeed the 130 and 210 proteins phosphorylated in EC upon VEGF treatment. The specificity of this interaction was demonstrated by co-immunoprecipitation experiments using an antibody against b2 microglobulin ( Figure 3a) . Similar results were obtained by using microvascular cells (CDC-HMEC-1 cells) (data not shown). These data are further confirmed by the time-course experiment on the anti-IL-3R bc immunoprecipitates performed with EC or H-END cells treated with VEGF (panel b) and in HEK 293 cells cotransfected with IL-3R and KDR (panel c). Moreover, we found that in HEK 293 cells expressing both D455 IL-3R mutant and KDR, VEGF treatment failed to induce the formation of the complex (panel d). However, in these cells, VEGF was still able to induce the activation of its own receptor, as shown by the anti-KDR immunoprecipitate. Similar results were obtained in H-END cells expressing the D455 mutant (data not shown).
We asked whether complex formation also occurred when vascular cells were stimulated with IL-3. To this end, microvascular ECs (CDC-HMEC-1 cells) and H-END cells were treated with IL-3 for different time intervals. As reported in Figure 4 , IL-3 was able to induce the formation of the IL-3R bc/KDR complex (panel a). Similar results were obtained in HEK 293 cells coexpressing both KDR and IL-3R (panel b). To investigate whether KDR enzymatic activity was required for complex formation, HEK 293 cells were transiently transfected with a kinase dead KDR mutant, as shown by the kinase assay reported in Figure 4c . In co-immunoprecipitation experiments with IL-3-and VEGF-treated cells, we found that both factors failed to induce the formation of the complex in cells expressing the inactive KDR (panel d). However, IL-3 still elicited the activation of its own receptor (panel e).
Thus, these data points to a redundancy of signals regulating neovessel formation where IL-3 and VEGF can act both directly, by activating the signaling pathways through their own receptor, and/or indirectly, by inducing a signaling cascade generated by receptor crosstalk.
Moreover, the observations that either inhibition of KDR kinase activity or the expression of the IL-3R D455 mutant prevent the formation of the complex indicate that this event strictly requires the integrity of both receptors.
Analysis of STAT5 tyrosine and serine phosphorylation
STAT proteins are the main regulators of cytokine receptor-mediated signals (Mui et al., 1995; Decker and Kovarik, 2000) . Besides tyrosine phosphorylation, serine phosphorylation also seems to modulate the activation of several STAT proteins (Yamashita et al., IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al 1998). As shown in Figure 5 , STAT5A, but not STAT5B, becomes tyrosine phosphorylated in response to IL-3 in Neo vector but not in D455-expressing cells (Figure 5b ). By contrast, we failed to detect STAT5 tyrosine phosphorylation in response to VEGF (Figure 5a ). The analysis of STAT5 serine phosphorylation in response to IL-3 and VEGF demonstrate that in Neo-vector-expressing cells, STAT5A was constitutively phosphorylated on serine, and that both IL-3 and VEGF were able to decrease the level of phosphorylation (panel c). On the contrary, both IL-3 and VEGF failed to lower the level of STAT5A serine phosphorylation in IL-3R D455-expressing cells and in cells expressing the kinase death KDR, suggesting that VEGF-untreated and -treated EC were lysed and IP with an anti-IL-3R bc antiserum or with an anti-KDR antiserum, as indicated. The anti-IL-3R bc immunoprecipitates were divided in two aliquots, subjected to SDS-PAGE and transferred to nitrocellulose filters. The filters were IB with an anti-phospho-tyrosine antibody (left panel) or with an anti-KDR antiserum (middle panel) and reblotted with the anti-IL-3R bc antiserum. After SDS-PAGE, the anti-KDR immunoprecipitates were IB with the anti-IL-3R bc antiserum and reblotted with the anti-KDR antiserum (right panel). As positive control, EC IP with the anti-IL-3R bc antiserum were used (c). In parallel experiments, cells were IP with the anti-IL-3R bc antiserum, the anti-KDR antiserum or with the anti-b2 microglobulin antibody. The filters were IB with the anti-IL-3R bc antiserum. 
IL-3 and VEGF enhance tumor dissemination by affecting neovascularization
H-END cells implanted in syngeneic mice typically form tumor similar to hemoangiosarcoma and Kaposi's sarcoma characterized by the presence of vascular structures and inflammatory cell infiltrates (Biancone et al., 1999) . To evaluate the effects of IL-3 and VEGF on an in vivo model, H-END cells were injected subcutaneously (s.c.) into syngeneic DBA/2 mice (five mice per group), and treated or untreated with IL-3 or VEGF. Within 5 weeks, all mice developed a visible primary tumor mass, associated with secondary metastases as reported previously (Biancone et al., 1999) . The mean of tumor diameter and of the number of metastases are reported in Table 1 . In line with the observation that VEGF and IL-3 did not induce proliferation, no differences in tumor diameter were detected between treated and untreated mice. On the contrary, the number of secondary tumor masses was much higher in the IL-3-and VEGF-treated mice than in the control. Consistent with in vitro results, in D455 H-END cell-bearing mice, the effect of IL-3 and VEGF on tumor dissemination was abrogated or reduced, respectively. To confirm that tumor dissemination was dependent upon tumor neovascularization, vascular density inside tumors was also determined. As shown in Figure 6e , quantification of tumor neovascularization demonstrated that either IL-3 or VEGF treatment led to increased vascular density in tumor of Neo-vector H-END cell-bearing mice. On the contrary, a reduced vascular density was detected in tumors from IL-3R D455 mutant cells. Moreover, a slight increase in the number of vessels inside these tumors was detected upon VEGF but not IL-3 treatment. These results are also sustained by the analysis of KDR expression in tumors derived from Neo-vector and IL-3R D455-bearing mice (Figure 6f) . Consistent with the decrease in tumor IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al neovascularization, areas of necrosis could be detected in the same sections (panels c and d) and a decrease in tumor size could also be observed (Table 1) . No necrotic area was found in tumor sections from mice injected with Neo H-END cells. The decrease in the number of vessels is also shown in the representative panels b-d when compared with panel a. Cells from in vitro-expanded secondary tumor masses were analysed for their original phenotype and shown in Figure 5d . Polymerase chain reaction (PCR) analysis demonstrates that the secondary lesions expressed the IL-3R D455 mutant.
Discussion
Several studies implicated IL-3 in the regulation of vascular pathophysiological processes such as atherogenesis and inflammation (Dentelli et al., 1999 (Dentelli et al., , 2004 . IL-3 was originally reported as an activated T-cellderived cytokine (Wimperis et al., 1989) . More recently, it has been shown that in noninvasive breast cancer tissues, IL-3 is also expressed by a subset of tumorinfiltrating CD25/CD4/CD5 þ T cells (Dentelli et al., 2004) . Moreover, the finding that IL-3 is also expressed by tumor-derived ECs (Deregibus et al., 2002; Bussolati et al., 2003) suggests a more pleiotropic role of this cytokine in tumor biology. Tumor angiogenesis has been currently regarded as potential therapeutic target. It is becoming clear from preliminary trials that tumor endothelium has distinct features compared with normal endothelium that may confer a potential resistance to antiangiogenic therapy (Kerbel, 2001a, b) . We herein demonstrate that transformed ECs exposed to IL-3 activate survival signals mediated by Akt and acquire the ability to migrate and to invade Matrigel containing collagen IV and laminin. Consistently, IL-3, as VEGF, affects tumor expansion in vivo. The angiogenic process is crucial for growth and invasion of tumor cells as IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al vasculature provides metabolic support for tumor cells and serves as a gatekeeper for their escape and entry into circulation (Carmeliet, 2003) . Thus, it is conceivable to postulate that apart from VEGF, IL-3, released into the tumor microenvironment, may enhance EC organization to form a network of neoformed vessels and allow tumor invasion and growth. Indeed, the following observations sustain this possibility: (i) IL-3 elicits cell migration and in vitro tube-like structure formation; (ii) the expression of the inactive IL-3R not only affects cell migration, invasiveness and the formation of tubelike structures but also the number of vessels inside tumor in vivo.
All aspects of cell motility and invasiveness are controlled by Rho GTPases, which are closely linked to signals from the extracellular environment (Burridge and Wennerberg, 2004) . Acquisition of a motile phenotype via the Rho GTPases family members is one requirement for the formation of new vessels (Chambers et al., 2002; Burridge and Wennerberg, 2004) . Here, we first demonstrate that Rac1 signaling pathway (Burridge and Wennerberg, 2004 ) is engaged by both IL-3 and VEGF. Moreover, our results indicate that the IL-3R bc is recruited by both IL-3 and VEGF to engage Rac1 and mediate EC motility in vitro and neovessel formation in vivo, indicating that the IL-3R bc can cooperate with KDR to control cell migration during neovessel formation.
VEGF released into the tumor environment is considered relevant for stimulation of growth and survival of tumor ECs (Liu et al., 2000) . Although VEGF binds to two different tyrosine kinase receptors: Flt-1 and KDR (Yancopoulos et al., 2000; Ferrara et al., 2003) , most biological functions of VEGF are mediated by KDR and the role of Flt-1 is currently only partially known. Binding of VEGF to KDR results in receptor dimerization and autophosphorylation of tyrosine in the cytoplasmic region (Guo et al., 1995) , creating docking sites for various Src homology 2 domain binding proteins. However, besides the canonical intracellular cascade of signaling molecules activated by KDR, a more intriguing scenario has been described (Yancopoulos et al., 2000; Ferrara et al., 2003) . Indeed, transactivation of KDR in response to bradykinin and sphingosine 1-phosphate have also been reported (Tanimoto et al., 2002; Thuringer et al., 2002) . We herein demonstrate that as the results of IL-3 and VEGF challenge, a KDR/IL-3R bc macromolecular complex is formed, and that the integrity of the receptors is required for this interaction. Moreover, we demonstrate that this event also occurs in microvascular cells. Thus, our results identify IL-3-and VEGF-mediated receptor transactivation as a novel molecular mechanism that can regulate neovessel formation in vivo.
STAT5s are the main targets of the IL-3R-mediated signals (Mui et al., 1995) . We demonstrate that, unlike IL-3, VEGF did not trigger STAT5 tyrosine phosphorylation; however, as IL-3, VEGF was able to regulate negatively STAT5A serine phosphorylation. Although serine phosphorylation positively modulates the transcriptional activity of STAT3 and STAT1, the functional and biological implications of STAT5A/B serine phosphorylation appear to be more complex (Yamashita et al., 1998; Decker and Kovarik, 2000) . So far, positive or negative modulator roles of STAT5A/B serine phosphorylation have been reported in different studies Micrographs show an increase in cellular components, a strong reduction of neovasculature and area of necrosis. (e) Effect of IL-3R D455 mutant expression on intratumor vessel area. The quantification of neovascularization was performed on hematoxylin-and eosin-stained section as described in Materials and methods and the results were expressed as percentage7s.d. of the vessel area to the total tumor area. Five different sections from each individual experimental group (six mice per group) were analysed. ANOVA with Newman-Keuls multicomparison test was performed: control vs experimental groups: *Po0.05. (f) Quantification of angiogenesis. Tumors from PBS, IL-3-or VEGF-treated mice were lysed and equal amount of proteins subjected to immunoprecipitation and immunoblotting with anti-VEGFR2/ KDR antibody IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al (Yamashita et al., 1998; Decker and Kovarik, 2000) . Our finding that IL-3 failed to lower STAT5 serine phosphorylation in D455 cells indicates that the IL-3R bc actively participates in serine dephosphorylation of STAT5A. The component that involves STAT5A serine dephosphorylation is intriguing. It can be speculated that the enzymatic activity of yet to be identified STAT5 serine kinase can modulate serine phosphorylation in response to IL-3R bc activation. This downmodulation might take place via the inactivation of specific kinases responsible for STAT5A serine phosphorylation, modulation of either their half-life or expression, or the activation of a specific phosphatase. Nevertheless, as shown for oncogenic RhoA (Benitah et al., 2003) and glucocorticoid-stimulated cells (Groner et al., 2000) , serine phosphorylation of STAT5A plays an inhibitory rather than stimulatory role among signals generated by the activation of IL-3R bc. This possibility is sustained by the following observations: (i) serine phosphorylation of STAT5A was constitutively present in H-END cells under normal serum condition; (ii) tyrosine phosphorylation and serine dephosphorylation of STAT5A occurred in response to IL-3; and as above reported (iii) tyrosine phosphorylation and serine dephosphorylation of STAT5A could not be detected in cells expressing the inactive IL-3R bc. Moreover, the observation that, as IL-3, VEGF failed to lower STAT5 serine phosphorylation in cells expressing the IL-3R D455 mutant or the kinase death KDR, identify STAT5 serine dephosphorylation as one of the downstream signaling events IL-3R mediated common to both VEGF and IL-3.
The current wisdom is that tumors are endowed with an angiogenic capability and that their growth, invasion and metastasis are angiogenesis dependent (Yancopoulos et al., 2000; Ferrara et al., 2003; Friedl and Wolf, 2003) . However, a growing body of evidences indicate that VEGF may also acts as survival factor for newly formed blood vessels (Liu et al., 2000) . In the present study, we provide evidences that, as VEGF, IL-3 activate survival pathways in tumor ECs. Moreover, we report that IL-3 activates Rac1, increases cell migration and tube-like structures in vitro and promotes the formation of the vascular network that favor tumor invasiveness in vivo. Finally, data presented herein first demonstrate that a physical interaction between IL-3R and KDR occurs in ECs exposed to IL-3 or VEGF, and that this molecular mechanism can modulate tumor angiogenesis. Overall, these findings suggest that activation of the IL-3R signaling may be critical in coordinating events associated with late-stage tumor development and make this pathway a potential target for novel therapeutic intervention in human cancer. RPMI medium, (Milan, Italy) . The presence of endotoxin contamination of IL-3 preparation was tested by the Limulus amebocyte assay and the concentration was o0.1 ng/ml.
Materials and methods
Reagents
Antisera
Anti-phospho-STAT5 antibody was from New England BioLabs (Beverly, MA, USA). Anti-phospho-STAT5 (serine725/730), anti-phospho-Akt and anti-Rac1 antibodies were from Upstate (Lake Placid, NY, USA). Anti-STAT5 C-17 or L-20 or G-2, anti-Akt, anti-b2 microglobulin and anti-KDR antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany). Rabbit polyclonal anti-hIL-3 antiserum was from R&D Systems (Minneapolis, MN, USA). Anti-phosphotyrosine mAb PY20 antibody was from Transduction Laboratories (Lexington, KY, USA). Polyclonal rabbit anti-IL-3R bc-subunit antiserum was prepared as described previously (Dentelli et al., 1999) . mAb 9E10 to the Myc epitope tag (purchased from ATCC) were affinity purified on protein A-Sepharose and their purity was higher than 95%.
Cell culture and transfection
Umbilical cord EC were isolated and characterized as described previously (Brizzi et al., 1993) . CDC-HMEC-1 cell line (Dentelli et al., 2004) was also used in some experiments. HEK 293 human epithelial cells, obtained from ATCC, and murine-derived H-END cells (Biancone et al., 1999) were stably transfected with the Neo vector, the full-length IL-3R bc (FL) or the myc-tagged IL-3R bc-deleted mutants (D455) (kind gift of Dr A Miyajima, Tokyo, Japan) (Sakamaki et al., 1992) . Transfections were performed by the lipofectin methods and selected with G418. Positive clones were selected by Western blot analysis with the IL-3R bc antibody (Dentelli et al., 1999; Bartoli et al., 2000) or mAb 9E10 to the Myc epitope, respectively. FL-IL-3R bc-and D455 HEK 293-expressing cells were also transiently transfected with the IL-3R a-subunit (Brizzi et al., 1994) (kindly provided by Dr T Kitamura, Tokyo, Japan) or with KDR (Terman et al., 1991) cloned in pEGFP-C1 vector. KDR cDNA was kindly provided by Dr Terman (Dougher and Terman, 1999) .
Site-directed mutagenesis of the KDR cDNA Synthetic oligonucleotides were chemically synthesized and employed as mismatched primers to introduce single mutation (at lysine 365 in the ATP-binding site). A two-step PCR strategy was used. In the first step, PCR reaction full-length KDR was used as a template. Reaction 1 includes the oligonucleotide primers 5 0 -CCA TCG TCA TGG ATC CAG ATG AA (5 0 to a unique BamHI site in KDR cDNA) and 3 0 -TC T TT CAA CAT TCT GAC TGC TAC TG (encompasses site of mutation that is underlined). Reaction 2 used the oligonucleotide primers 5 0 -CCA TCG TCA TGG ATC CAG ATG GAA (5 0 to a unique BamHI site in KDR cDNA) and IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al 3 0 -AAA GAC CAG ACG TCA CTC TGG A (3 0 to a unique AatII site in KDR cDNA). The PCR products were processed as described by Bowman et al. (1990) . The PCR products was cloned in TA cloning (Invitrogen) and subsequently digested with BamHI plus AatII and used to replace the BamHI/AatII fragment of the KDR cDNA. DNA sequencing was used to verify that no other mutations were introduced during these procedures. pcDNA 3.1 (À) hygroplasmid was used as expression vector for both the full-length and the KDR(K365). Transient expression of both receptors was carried out using Western blot analysis with an anti-KDR antibody. Transfection efficiency, evaluated by immunofluorescence, varies from 70 to 80% of plated cells.
Immunoprecipitation and Western blot analysis
EC monolayers, H-END and HEK 293 cells were serumstarved for 24 h at 371C and unstimulated or stimulated with VEGF (10 ng/ml) or IL-3 (20 ng/ml) for the indicated intervals. Cells were lysed in cold DIM buffer (50 mmol/l Pipes, pH 6.8, 100 mmol/l NaCl, 5 mmol/l MgCl 2 , 300 mmol/l sucrose, 5 mmol/l EGTA, 2 mmol/l sodium orthovanadate plus 1% Triton X-100 and a mixture of protease inhibitors/1 mmol/l phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 0.15 U/ml aprotinin and 1 mg/ml pepstatin (A). Equal amount of proteins (500 mg) were immunoprecipitated with different antibodies, as indicated, and the immunocomplexes were bound to protein A-Sepharose beads. Bound proteins were eluted and processed as described previously (Brizzi et al., 2001) . For Western blot analysis after lysis, protein concentration was obtained as described previously (Brizzi et al., 2001) .
Migration assay
Migration assay was performed in Boyden's chambers and in vitro angiogenesis on Matrigel (from Becton Dickinson Labware)-coated surface as described (Dentelli et al., 1999) . To evaluate cell viability, Trypan blue exclusion staining was performed at the end of the experiments.
Matrigel/collagen IV invasion assay
Matrigel, which does not contain growth factors and is primarily composed of human collagen IV, collagen I, laminin and fibronectin, were prepared according to the manufacturer's directions (Becton Dickinson). Invasion assays were performed as described by Konecny et al. (2001) . Approximately 75 ml was used to coat 8-mm pore membrane transwell 24-culture dishes (Costar). Wild-type H-END or the indicated transfectants (7.5 Â 10 5 ) were loaded onto the top chamber in serum-free media and IL-3, VEGF or bFGF were used as chemoattractants in the bottom chamber. The number of cells reaching the bottom chamber were quantitated by direct visual cell count after 24 and 48 h at Â 200 magnification.
In vitro kinase assay
Anti-KDR immunoprecipitates were washed and divided into two equal parts. One part was resuspended in an equal volume of Kinase assay buffer (50 mM NaCl, 5 mM MgCl 2 , 0.1 mM Na 3 VO 4 , 10mM HEPES (pH 7.4)) containing [g-32 P]ATP (0.25 mCi/ml) for 30 min at room temperature, washed, eluted with sample buffer for SDS-PAGE, separated on 8% gel and visualized by autoradiography, and the other part was separated on 8% gel and probed with anti-KDR antiserum.
Evaluation of tumor growth in vivo
For the in vivo experiments, 10 7 cells of H-END cells expressing Neo vector or the IL-3R D455 mutant were injected s.c. into left back of the syngeneic DBA/2 mice. Three groups of mice (each of five mice) were untreated (saline) or treated with VEGF (20 mg) or IL-3 (20 mg) injected s.c. within tumors once a week for 4 weeks (Rofstad and Halsor, 2000) . Tumor size will be documented by measuring two perpendicular diameters in millimeters using a caliper. Animals have been killed at 4-5 weeks end points and subjected to autopsy. All organs were examined macroscopically for evidence of tumor growth. Tissue containing visible tumor growth have been fixed for light microscopy and immunohistochemical studies (Brizzi et al., 2001) . Secondary tumor masses have also been cultured and examined for the expression of the IL-3R D455 mutant. Vessel area and the total tumor area were planimetrically assessed from stained sections as described by Kibbey et al. (1992) . Vessels considered were only those structures possessing a patent lumen and containing RBC. Results were expressed as the percentage of the vessel area to the total tumor area. Alternatively, to quantify angiogenesis, tumors were lysed in RIPA buffer containing protease and phosphatase inhibitors and proteins were immunoprecipitated and subjected to immunoblotting with anti-VEGFR2/KDR antibodies. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources (National Institutes of Health publication no. 93-23, revised 1985) .
Analysis of explanted metastasis
Metastasis diameters were measured independently by two observers and the numbers were averaged. Metastasis (five for each mice) explanted from each group of mice has been incubated with 0.03% collagenase, 0.03% trypsin and 20 mg/ml of Dnase (all from Sigma), and then cultured in M199 with the addition of 5% BCS. The expression of the IL-3R D455 mutant was evaluated by PCR or by Western blot analysis.
Assay for Rac1-GTP loading
H-END cells expressing Neo vector, FL-IL-3R bc or IL-3R D455 mutant were serum deprived for 24 h and untreated or treated with IL-3 or VEGF. Cells were lysed for 5 min at 41C in 1% NP-40, 50 mM Tris, pH 7.4, 10% glycerol, 100 mM NaCl and 2 mM MgCl 2 in the presence of protease inhibitors. Lysates were clarified by centrifugation and incubated with recombinant-GST-PAK precoupled to Sepharose-glutathione beads (Amersham, Pharmacia Biotech) for 30 min a 41C and then washed three times in lysis buffer (Benard et al., 1999) . The GST-PAK precoupled Sepharose-glutathione beads used to pull down GTP-bound Rac1 from cleared lysates of cells were boiled in Laemmli sample buffer and proteins samples separated by SDS-PAGE and transferred to nitrocellulose filters. The filters have been probed with an anti-Rac1 antibody and developed by enhanced chemiluminescence.
PCR analysis
Reverse transcription-polymerase chain reaction (RT-PCR) was used to screen secondary lesion masses. Briefly, cytoplasmic RNA was isolated from cells by guanidinium thiocyanate/ acid phenol-chloroform extraction (Chomczynski and Sacchi, 1987) . After DNAse digestion, RNA was subjected to RT-PCR, at 601C of annealing temperature for 35 cycles of amplification, with specific primers for FL-IL-3R bc: 5 0 -AGCAA GAGCCACGAATTCCAGAACGGG-3 0 ; 5 0 -TGAGGCAGC TCGAGTCGTGTC-3 0 ; and for IL-3R mutant D455: 5 0 -GG IL-3R/KDR interaction affects tumor neovascularization P Dentelli et al TCCCCCAGGTCACCAAGGACC-3 0 ; 5 0 -GGCAACTAGA AGGCACAGTCGAGG-3 0 , the latter includes the myc-tag. Amplification products were analysed in 1.5% agarose gels. As positive controls, H-END cells injected in mice were used.
Statistical analysis
All in vitro results are representative of at least three independent experiments performed in triplicate. Densitometric analysis using a Bio-Rad GS 250 molecular imager was used (data not shown) to calculate differences in the fold induction of protein activation or expression (Po0.05, statistically significant between experimental and control values). Significance of differences between experimental and control values was calculated using ANOVA with NewmanKeuls multicomparison test.
